Kasamatsu Ayu, Yahata Yuichiro, Fukushima Wakaba, Sakamoto Hirofumi, Tanaka Kaori, Takigawa Miwa, Izu Kaori, Nishino Yuko, Suzuki Motoi, Kamiya Hajime
Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, J1601 Iidabashi Plano Stage Building, 2-7-2 Fujimi, Chiyoda-ku, Tokyo 102-0071, Japan.
Center for Field Epidemic Intelligence, Research, and Professional Development, National Institute of Infectious Diseases, J1601 Iidabashi Plano Stage Building, 2-7-2 Fujimi, Chiyoda-ku, Tokyo 102-0071, Japan.
Vaccine. 2024 Dec 2;42(26):126488. doi: 10.1016/j.vaccine.2024.126488. Epub 2024 Oct 31.
Japan lacks an established framework for routine seasonal influenza vaccine effectiveness (SIVE) assessment at the national and municipal levels. This study aimed to estimate SIVE among older adults using an innovative population-based administrative database linking medical fee claims data with vaccination records, while also exploring its potential bias.
In this retrospective population-based cohort study, we assessed SIVE against medically attended influenza during the 2017/18 season among older adults aged ≥65 years in a Japanese city. A Cox proportional hazards model was used to estimate hazard rate ratios, treating vaccination status as time-dependent. To explore potential biases, multivariate logistic regression analysis was used to investigate the association between vaccination status and acute respiratory infection (ARI) diagnosis and trauma/injury during the non-influenza season.
This study included 82 % (n = 110,892) of the city's older adult population, with 39.7 % vaccination coverage. The estimated SIVE was 2.9 % (95 % confidence interval: -6.2-11.2), showing no statistical significance. Similarly, subgroup analyses by age and comorbidities revealed no significant protective effect of SIVE. In the non-season analysis, adjusted odds ratios of vaccination were significantly higher for ARI [1.3 (1.3-1.4)] and trauma/injury [1.2 (1.1-1.2)]. However, no significance was observed for hospitalizations with these diagnoses, which include severe conditions less associated with healthcare-seeking behaviors [0.9 (0.8-1.1) and 0.8 (0.6-1.0), respectively].
No significant SIVE was observed during the 2017/18 season. Our real-world observational study, based on medical fee claims data, indicates a potential underestimation of SIVE owing to bias related to healthcare-seeking behaviors.
日本在国家和市级层面缺乏常规的季节性流感疫苗有效性(SIVE)评估框架。本研究旨在利用一个创新的基于人群的行政数据库,将医疗费用报销数据与疫苗接种记录相链接,来估计老年人中的SIVE,同时探讨其潜在偏差。
在这项基于人群的回顾性队列研究中,我们评估了日本一个城市中65岁及以上老年人在2017/18季节针对就医流感的SIVE。使用Cox比例风险模型估计风险率比,将疫苗接种状态视为随时间变化的因素。为了探讨潜在偏差,采用多变量逻辑回归分析来研究疫苗接种状态与非流感季节急性呼吸道感染(ARI)诊断及创伤/损伤之间的关联。
本研究纳入了该市82%(n = 110,892)的老年人口,疫苗接种覆盖率为39.7%。估计的SIVE为2.9%(95%置信区间:-6.2 - 11.2),无统计学意义。同样,按年龄和合并症进行的亚组分析也未显示SIVE有显著的保护作用。在非季节分析中,ARI [1.3(1.3 - 1.4)]和创伤/损伤[1.2(1.1 - 1.2)]的疫苗接种调整优势比显著更高。然而,对于这些诊断的住院情况未观察到显著性,这些住院情况包括与就医行为关联较小的严重病症[分别为0.9(0.8 - 1.1)和0.8(0.6 - 1.0)]。
在2017/18季节未观察到显著的SIVE。我们基于医疗费用报销数据的真实世界观察性研究表明,由于与就医行为相关的偏差,SIVE可能被低估。